Referral process

If you are a provider looking to refer a patient to our program, please complete our referral form.

If your patient is eligible, we contact them to discuss details about the transplant process and to schedule an evaluation. Once we complete the evaluation, we inform you of your patient’s test results and give you our recommendations regarding their suitability for transplant.

Kidney/pancreas transplant referral 

Our kidney/pancreas transplant team performs hundreds of transplants per year. We ensure every patient receives highly coordinated, personalized care.

Kidney/pancreas transplant referral form

Liver transplant referral 

We have decades of experience providing comprehensive liver care to patients before, during and after liver transplant. Our liver transplant program is part of the gastroenterology and GI surgery program nationally ranked by U.S. News & World Report.

Liver transplant referral form

Heart transplant referral 

Our heart transplant program is part of the cardiology and heart surgery program nationally ranked by U.S. News & World Report. We’ve performed over 1,000 successful heart transplants, giving us premiere expertise and experience.

Heart transplant referral form

Lung transplant referral guidelines

Our transplant program has performed over 2,000 lung transplant surgeries, gathering worldwide recognition. Lung transplant evaluation can be intensive and complex. Our guidelines for referral include:

Interstitial Lung Disease and Pulmonary Fibrosis
  • At the time of diagnosis of IPF/UIP based on a biopsy or CT scan findings

  • Any form of fibrosis with FVC < 80% predicted or DLCO < 40% predicted

  • Decline in FVC ≥ 10% over the past 2 years

  • Decline in DLCO ≥ 15% over the past 2 years

  • Need for supplemental oxygen at rest or with exertion

Cystic Fibrosis
  • FEV1 below 30% predicted or a rapid decline in FEV1 

  • Exacerbation of pulmonary disease requiring ICU stay

  • Increasing frequency of exacerbations requiring antibiotic therapy

  • Refractory and/or recurrent pneumothorax

  • Recurrent hemoptysis not controlled by embolization

  • Any form of fibrosis with FVC < 80% predicted or DLCO < 40% predicted

  • Decline in FVC ≥ 10% over the past 2 years

  • Decline in DLCO ≥ 15% over the past 2 years

  • Need for supplemental oxygen at rest or with exertion

COPD and Alpha-1 Antitrypsin Deficiency Emphysema
  • BODE score 5-6

  • Frequent acute exacerbations

  • Increase in BODE score > 1 over 24 months

  • FEV1 in the range of 20-25% predicted

  • Pulmonary artery to aorta diameter > 1 on CT scan

Pulmonary Arterial Hypertension
  • NYHA functional class III or IV, irrespective of ongoing therapy

  • ESC/ERS intermediate or high risk, or REVEAL risk score 8 despite appropriate therapy

  • Significant RV dysfunction despite appropriate PAH therapy

  • Need for IV or SC prostacyclin therapy

  • Progressive disease despite appropriate therapy or hospitalization for PAH symptoms

  • Known or suspected high-risk variants such as PVOD or scleroderma

  • Signs of secondary liver or kidney dysfunction due to PAH

  • Recurrent hemoptysis

Additional General Guidelines
  • Patients must be free from all nicotine product usage for at least six months (including e-cigarettes, vapor cigarettes, chew, gum, patches, etc.)

  • Acceptable weight status, usually BMI < 35 kg/m2

Lung transplant referral form

Locations

Schedule your appointment

Call  (314) 362-9355  or  (800) 392-0936  for more information about our transplant services or to schedule an appointment.

Sign up for our newsletter and take charge of your whole health.

Stay ahead of the curve with exclusive content from BJC's health care professionals, delivered right to your inbox.